Adjuvant trastuzumab in early HER2-positive breast cancer: Journeying towards the optimal duration of therapy in South Africa.
This article explores and reports on the data used to make this policy amendment.
PMID: 32657737 [PubMed - as supplied by publisher]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
More News: African Health | Breast Cancer | Budgets | Cancer | Cancer & Oncology | HER2 | Herceptin | South Africa Health | Toxicology